Intellectual Property Infringement and Defence Insurance for Indian Technology, Pharma and Manufacturing Firms in 2026

Intellectual property has moved from a legal-department concern to a balance-sheet exposure for a large part of Indian industry. A software firm shipping a product into the United States, a generic manufacturer filing an abbreviated new drug application, a consumer-electronics maker selling under a brand, and a specialty manufacturer with a patented process all carry the risk that a third party alleges their product, process or branding infringes a patent, a trademark or a copyright. The allegation does not have to be correct to be expensive: defending an IP suit in a jurisdiction like the United States runs into millions of dollars in legal fees before any question of damages, and the cost of the defence alone can be enough to threaten a mid-sized firm.

The exposure has grown for structural reasons. Indian technology and pharmaceutical firms increasingly earn the bulk of their revenue from export markets where IP litigation is a normal commercial tool, and where a competitor or a non-practising entity may sue to slow a market entrant or to extract a settlement. The shift toward software, platforms and branded products means more of the value of an Indian firm sits in intangible assets that can be challenged, and the rise of generative AI has added a fresh layer of copyright and IP uncertainty around training data and generated output. A firm that historically competed on cost and never worried about IP now finds that scaling into branded, patented or platform business brings IP risk with it.

The Indian legal position adds its own dimension. Patent, trademark and copyright are governed by the Patents Act 1970, the Trade Marks Act 1999 and the Copyright Act 1957, and Indian courts, including the Commercial Courts and the High Courts exercising IP jurisdiction after the abolition of the Intellectual Property Appellate Board, hear infringement and passing-off suits. Domestic IP litigation is rising, but the larger financial exposure for export-facing firms is foreign litigation, where the costs and the damages are an order of magnitude higher. IP insurance, still a specialty and nascent product in India, exists to absorb the cost of defending these allegations and, in its enforcement form, to fund the pursuit of infringers.

The core IP insurance product is infringement-defence cover, which responds when a third party alleges that the insured's activities infringe the third party's intellectual property. It is a liability cover: it meets the legal costs of defending the allegation and, depending on the wording, the damages or settlement the insured becomes liable to pay. The trigger is a claim made against the insured during the policy period, so the cover is written on a claims-made basis, like most specialty liability lines, and the date the claim is first made, not the date of the alleged infringement, determines which policy responds.

What the cover pays for breaks into parts. The largest and most certain element is defence costs: the legal fees, expert fees and court costs of fighting the allegation, which in a serious foreign patent suit dominate the economics. The second element is damages and settlements: the amount the insured is ordered or agrees to pay if the allegation succeeds or is settled, subject to the policy limit and the insurer's consent to settle. Some wordings extend to costs of redesign or modification to avoid continuing infringement, and to profits the insured is required to account for, though these are more variable across the market.

The scope of IP covered has to be read carefully. A policy may cover patents, trademarks, copyright, designs and trade secrets, or it may be narrower, and patent infringement, the most expensive and technically complex, is often the hardest and most expensive part of the cover to obtain. The territorial scope matters as much as the IP scope: a cover that responds to Indian litigation but excludes the United States is of limited value to an export-facing firm, and conversely worldwide cover including the US carries a much higher premium. The insured's own IP position is underwritten closely, because an insurer writing infringement-defence cover is taking on the risk that the insured did not adequately clear its product, brand or process against existing rights.

The mirror image of defence cover is IP-enforcement cover, also called pursuit or abatement cover, which funds the insured's own action against a third party that is infringing the insured's intellectual property. Where defence cover protects a firm being sued, enforcement cover protects a firm whose patents, trademarks or designs are being copied and which wants to stop the infringer but is deterred by the cost of litigation. For an Indian firm that has invested in developing patented technology or a valuable brand, the ability to enforce those rights is part of what makes the investment worthwhile, and the cost of enforcement is often what prevents a smaller rights-holder from acting against a larger infringer.

Enforcement cover works differently from defence cover because the economics are different. In defence, the insured is a reluctant defendant facing costs it did not choose; in enforcement, the insured is choosing to litigate, and an insurer funding that choice wants to share in the discipline of the decision. Enforcement policies therefore commonly involve the insurer assessing the merits of the proposed action before agreeing to fund it, fund the litigation costs up to a limit, and in some structures recover a share of any damages or settlement the insured wins, so that the cover behaves partly like litigation funding. The insurer is, in effect, backing the strength of the insured's IP and the prospects of the claim.

For the Indian market, enforcement cover is even more nascent than defence cover, and capacity is limited and selective. It is most relevant to firms whose competitive position depends on enforceable IP: a firm with a patented process that a competitor is copying, a brand owner facing counterfeiting, or a technology firm whose design is being imitated. The value of the cover is that it changes the negotiating position: an infringer who knows the rights-holder has funded enforcement behind it cannot rely on the rights-holder's inability to afford litigation, which often brings a faster and better settlement. Defence and enforcement are sometimes offered together as a combined IP programme, recognising that a firm with valuable IP is both a potential defendant and a potential claimant.

The shape of IP exposure differs sharply by sector, and the cover that matters depends on where a firm's intangible value and its infringement risk sit.

Technology and software firms

Technology firms carry exposure across all three rights but most acutely around patents and copyright. A software product or platform may be alleged to infringe a software or business-method patent, a risk concentrated in the United States where such patents and the non-practising entities that assert them are common. Copyright exposure arises around code, content and, increasingly, the data used to train and the output produced by generative AI systems, an area of genuine legal uncertainty. Trademark exposure attaches to product and brand names. For an Indian IT services or product firm earning from US and European clients, the foreign-litigation exposure dominates, and the cover has to include those territories to be meaningful.

Pharmaceutical and life-sciences firms

For Indian generic and specialty pharmaceutical firms, patent exposure is the defining IP risk. The generics model involves challenging or designing around originator patents, and patent litigation, particularly in the United States under the Hatch-Waxman framework, is a structural feature of the business rather than an occasional event. The stakes are high because a patent injunction can keep a product off a market entirely, and the litigation costs are among the largest in any IP dispute. Pharmaceutical IP exposure interacts with the firm's product liability and regulatory exposure, so IP cover is one part of a broader specialty programme for an exporting pharma firm.

Manufacturing and consumer-products firms

Manufacturers face exposure around patented processes and components, registered designs and brand trademarks. A specialty manufacturer using a patented process, a maker of branded consumer goods, or a firm whose product design is protected all carry infringement risk, both as potential defendants and, where they hold the rights, as potential enforcers against copiers and counterfeiters. The exposure is often domestic and regional as well as in export markets, and counterfeiting of established Indian brands is a recurring enforcement problem that pursuit cover is designed to address.

Across all three sectors, the common thread is that the firms most exposed are those whose value has shifted into intangibles and whose business reaches markets where IP is actively litigated. A firm selling an unbranded commodity into a domestic market has little IP exposure; a firm selling a branded, patented or platform product into export markets has a great deal.

IP cover does not sit in isolation; it overlaps with technology errors-and-omissions and product liability cover, and understanding the overlaps prevents both gaps and wasteful duplication.

Technology errors-and-omissions

Many technology errors-and-omissions (tech E&O) policies, written for software and IT services firms, include some IP infringement cover, typically for copyright, trademark and sometimes patent infringement arising from the insured's products or services. For a technology firm, the tech E&O policy may therefore be the first place IP cover appears, bundled with the cover for professional failures and service defects. The limits and the scope of the IP element within a tech E&O policy are often narrower than a standalone IP policy, and patent cover within tech E&O is frequently limited or excluded, so a firm with serious patent exposure cannot assume its tech E&O policy is enough. The interaction has to be mapped: where does the tech E&O IP grant end and where does a standalone IP policy begin, and which responds to a given claim. A firm that buys both without reconciling them risks paying twice for the same cover or, worse, discovering an uncovered gap between them. The design of a firm's [professional indemnity and errors-and-omissions programme](/insurance/professional-indemnity) should account for the IP element explicitly.

Product liability

Product liability cover responds to bodily injury or property damage caused by a defective product, and it generally excludes pure economic loss and IP infringement. A claim that a product infringes a patent is not a product liability claim, because there is no injury or physical damage; it is an IP claim. The two covers therefore address different exposures on the same product: product liability for the harm the product causes, IP cover for the allegation that the product infringes a right. A pharmaceutical or manufacturing firm needs both, and the boundary between them is usually clean, but the firm should confirm that its product liability wording does not inadvertently purport to cover, or exclude in a way that creates confusion, the IP exposure that the IP policy is meant to carry.

Reading the programme as a whole

The practical task for a buyer and its broker is to read the tech E&O, product liability and any standalone IP cover together, identify which policy responds to each type of IP and non-IP claim, and confirm that the territorial scope is consistent across them. A US patent suit against a software product, for example, has to land somewhere with adequate limits and US territorial cover, and the worst outcome is for each policy to point at another. Mapping the covers against the firm's actual exposure, by IP type and by territory, is the way to build a programme that responds when a claim arrives.

IP insurance in India is a specialty and developing line, and the way it is placed reflects that. The domestic market for standalone IP infringement and enforcement cover is thin: few Indian insurers write meaningful standalone IP capacity, and the appetite that exists is cautious, because IP is a technically demanding class to underwrite and the largest exposures sit in foreign jurisdictions that Indian insurers are not well placed to assess. As a result, a significant part of the IP cover Indian firms buy is placed into the global specialty market, through reinsurance, through the London market and Lloyd's, and through international insurers with dedicated IP underwriting teams.

This reliance on global capacity has practical consequences for buyers. The cover is often arranged through brokers with access to the international specialty market rather than off a domestic insurer's shelf, the wordings follow international IP forms rather than standardised Indian wordings, and the pricing and terms reflect the global IP market rather than the domestic general-insurance market. The underwriting is detailed: insurers assess the insured's IP, its freedom-to-operate and clearance processes, its litigation history, the territories it sells into, and the strength of its IP management, and they price and structure the cover accordingly. For patent cover in particular, the underwriting can involve technical assessment of the relevant prior art and patent field, which is why standalone patent cover is the hardest part of the market to access and the most expensive.

What this means for an Indian buyer

A buyer should approach IP cover as a specialty placement that requires preparation. The firm needs to be able to demonstrate that it manages its IP risk: that it conducts freedom-to-operate and clearance searches before launching products or brands, that it has a process for handling third-party rights and cease-and-desist letters, and that it does not have known unreported circumstances. The quality of this preparation affects both whether cover is available and what it costs, because the insurer is underwriting the discipline of the firm's IP management as much as the IP itself.

IP cover is not for every firm, and a broker advising on it should be clear about which clients genuinely need it and which do not. The exposure concentrates in firms whose value has moved into intangibles and whose business reaches markets where IP is litigated, so the cover matters most to a specific profile.

The firms that most need IP cover are: technology and software firms selling products or platforms into the United States and Europe, where software-patent and copyright litigation is active; generic and specialty pharmaceutical firms exporting into markets with structural patent litigation; branded consumer-products firms whose trademarks and designs are both an asset to enforce and an exposure to defend; and specialty manufacturers using or holding patented processes. For these firms, the question is which form of cover (defence, enforcement or both), at what limit and in which territories, and how it sits alongside their tech E&O and product liability programmes.

The firms that need it least are those selling unbranded, unpatented commodities into domestic markets, where the intangible value and the litigation exposure are both low. Between the two ends sit many mid-sized firms that are scaling into branded or export business and acquiring IP exposure as they do, for whom the right moment to consider cover is as that transition happens, not after a cease-and-desist letter arrives.

Building the placement on real wording detail

IP cover is wording-driven: the IP types covered, the territorial scope, the claims-made trigger and prior-circumstances exclusion, the defence-costs treatment, and the interaction with tech E&O and product liability all turn on the precise terms, and those terms vary widely across the global specialty forms used. A broker placing IP cover for an Indian technology, pharma or manufacturing client has to compare these terms across the available markets and reconcile them against the client's other specialty policies, so that the programme responds to a real IP claim in the right territory with adequate limits.

Sarvada gives commercial insurance brokers structured, searchable access to insurer policy wordings, so the IP, technology E&O and product liability covers in a client's programme can be compared on their triggers, IP-type grants, territorial scope and exclusions, and reconciled into a programme without gaps or duplication. As IP becomes a balance-sheet exposure for more of Indian industry, that wording-level depth is what lets a broker advise credibly on a specialty line that is still finding its feet in the Indian market. Request Access to bring that depth to your IP and specialty placements.